Nod for Bharat Biotech’s intranasal ‘five arms’ Covid-19 booster

DCGI go-ahead for restricted use, say reports

0
24
Vaccine
DCGI has given emergency use authorization to the nasal vaccine iNCOVACC for restricted emergency

India’s drug controller has approved vaccine manufacturer Bharat Biotech‘s intranasal ‘five arms’ Covid-19 booster dose for restricted use, news agency IANS and ANI reported citing sources.

The Drugs Controller General of India (DCGI) has given emergency use authorization to the nasal vaccine iNCOVACC for restricted emergency use as the third dose for adults irrespective of whether they had been administered the Covaxin or Covishield vaccine doses, the report said.

The DCGI was yet to issue any official statement when this report was filed on 25 November.

Reports were earlier doing rounds in the media that DCGI’s subject expert committee held discussions on the booster dose on 15 November after Bharat Biotech International had applied for market authorization.

The pharma company in a statement has said the iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein.

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here